Human Longevity, Celgene Ink Placental Stem Cell Deal – Genetic Engineering & Biotechnology News
|
Human Longevity, Celgene Ink Placental Stem Cell Deal
Genetic Engineering & Biotechnology News Human Longevity (HLI), the genomics and cell therapy-based diagnostic and therapeutic company that J. Craig Venter, Ph.D., recently co-founded, has made a deal with Celgene Cellular Therapeutics (CCT) to license, develop, and co-promote Celgene's … Human Longevity, Inc. and Celgene Cellular Therapeutics Sign License … |
